Overview

Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer

Status:
Active, not recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This phase III trial studies how well dexamethasone works in reducing everolimus-induced oral stomatitis in patients with cancer. Dexamethasone may help to reduce the everolimus-induced oral stomatitis so as to improve quality of life in cancer patients.
Phase:
Phase 3
Details
Lead Sponsor:
Alliance for Clinical Trials in Oncology
Collaborator:
National Cancer Institute (NCI)
Treatments:
BB 1101
Dexamethasone
Dexamethasone acetate
Everolimus
Sirolimus